Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists
Authors:
Open Access
- 27 May 2019
- journal article
- review article
- Published by Taylor & Francis in Hospital Practice
- Vol. 47 (3) , 113-122
Abstract
Direct oral anticoagulants (DOACs) include dabigatran etexilate, a direct thrombin inhibitor, and specific inhibitors of activated coagulation factor X (FXa; e.g. apixaban, betrixaban, edoxaban, rivaroxaban). DOACs are associated with lower rates of major and fatal bleeding events compared with warfarin. Clinicians may need to achieve rapid reversal of anticoagulation effects of the DOACs in an emergency setting. Idarucizumab and andexanet alfa, which reverse the anticoagulant effects of dabigatran and FXa inhibitors, respectively, are DOAC reversal agents available in the US. Other reversal agents (e.g. ciraparantag for heparins, DOACs) are in development. Alternative nonspecific agents (e.g. fresh frozen plasma, prothrombin complex concentrate) are available. Nonspecific prohemostatic agents can counteract the anticoagulant action of DOACs in emergency situations, when specific reversal agents are unavailable. However, specific reversal agents are efficacious and safe and should be preferred when available. In this review, we discuss practical issues in the initiation of DOAC therapy, situations where reversal may be needed, coagulation assays, reversal agents, and post-reversal complications in the context of published evidence and guidelines.Keywords
This publication has 43 references indexed in Scilit:
- Antithrombotic Therapy for Atrial FibrillationChest, 2018
- The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillationEuropean Heart Journal, 2018
- Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillationJournal of Cardiology, 2017
- Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysisThe American Journal of Medicine, 2017
- Safety of Direct Oral Anticoagulants: Insights from Postmarketing StudiesThe American Journal of Medicine, 2016
- Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta‐AnalysisJournal of the American Heart Association, 2016
- How to effectively manage the event of bleeding complications when using anticoagulantsExpert Review of Hematology, 2015
- Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous ThromboembolismJournal of Cardiovascular Pharmacology and Therapeutics, 2015
- Evidence-Based Management of Anticoagulant TherapyChest, 2012
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009